Resolution Therapeutics presented preclinical evidence that RTX001, an engineered macrophage therapy, reduces liver inflammation, fibrosis, and enzyme elevation in mouse models. The data support progression toward Phase I/II human trials, positioning cell-based immunomodulation as a potential intervention for advanced liver disease.
Key Points
- RTX001 reduced liver fibrosis and inflammation markers in preclinical models
- Engineered macrophages demonstrated anti-inflammatory and anti-fibrotic pharmacology
- Safety profile supports advancement to human Phase I/II trials in 2026
Longevity Analysis
Liver regeneration and immune tolerance are central to sustained health across the lifespan. Fibrosis, the pathological stiffening of tissue that characterizes end-stage liver disease, represents a failure of the body's regenerative capacity and a dysregulated defense response. Rather than attempting to suppress immune activity broadly, this approach engineers immune cells to actively resolve inflammation and restore tissue integrity — a mechanism closer to how young tissue repairs itself. If the pharmacokinetic profile remains favorable in human studies, this strategy offers a fundamentally different pathway than conventional immunosuppression or liver transplantation, potentially restoring functional capacity rather than managing decline.
Original published by LT Wire.